Clinical Trials Logo

Clinical Trial Summary

Patients with average or high average peritoneal glucose transport status be included in the study as mentioned in the inclusion and exclusion criteria. The change in peritoneal glucose transport will be evaluated before and after one month treatment with 10 mg of Dapagliflozin. Peritoneal Equilibration Test (PET) test for patients before and after Dapagliflozin use and volume status of patients as measured by ultrafiltration from peritoneal dialysis exchanges. The aim of the trial is to determine whether dapagliflozin can decrease glucose absorption from peritoneal fluid and reduce plasma glucose absorption from the PD fluid and thus improve ultrafiltration with a reduction in intraperitoneal glucose exposure


Clinical Trial Description

The research targets patients on peritoneal dialysis with average and high transport status documented by Peritoneal Equilibrium Transport Test (PET test) in Najah National University Hospital. Research participants will be recruited from the patients on peritoneal dialysis in NNUH. A study team member will prescreen the patient based upon the inclusion/exclusion criteria. If potentially eligible, the coordinator will approach candidates directly to provide information about the study and to invite them to voluntarily participate. The primary investigator will provide the participant with the informed consent document to read to read and to sign it if they agree to participate. The study includes patients on peritoneal dialysis with average and high transport status documented by Peritoneal Equilibrium Transport Test (PET test). Prior to starting treatment with Dapagliflozin all patients included in the study population will have the following tests performed: Modified Peritoneal Equilibrium Test with 4.5% Dextrose peritoneal fluid Hemoglobin A1C levels 24 urine collection for protein, glucose, and creatine clearance Peritoneal fluid albumin levels Patients will report daily ultrafiltration volumes one week prior to the start of treatment Blood pressure, heart rate and weight of patients prior to the start of treatment Sodium sieving will estimated by subtracting the sodium dialysate concentration at time zero from the sodium dialysate concentration at one hour. Uric Acid levels Patients will then start on Dapagliflozin 10 mg daily for 4 weeks. During the study period patients will be evaluated for any side effects including; Volume Depletion Ketoacidosis Hypoglycemia Urinary Tract infections Uric Acid levels Discontinuation of drug due to Adverse Events (DAEs) Changes in clinical chemistry/hematology parameters Adverse events of interest (volume depletion, major hypoglycemic events, fractures, diabetic ketoacidosis, genital and urinary tract infections) Patients will monitored for the following: Glucose levels Bicarbonate levels Blood pressure readings Hemoglobin A1C levels every 4 months. Depending on the volume of ultrafiltration per patient and patient's weight, the investigators will have the choice to change the prescription; as per the investigator clinical judgment. For example if a patient with a four PD exchanges using 2.5% dextrose which yielded about 1.5L of ultrafiltration daily, and once started on Dapagliflozin had an increase ultrafiltration of 2.3 L a day, the investigator will be able to adjust the prescription to include 1.5% exchanges; resulting in less ultrafiltration volume. At the end of the study period patient will be evaluated for the following: Modified Peritoneal Equilibrium Test with 4.5% Dextrose peritoneal fluid 24 urine collection for protein, glucose, and creatine clearance Peritoneal fluid albumin levels Blood pressure, heart rate and weight of patients prior to the start of treatment Sodium sieving will estimated by subtracting the sodium dialysate concentration at time zero from the sodium dialysate concentration at one hour. Uric acid levels The collection of all blood pressure, hear rate reading and weights of patients will be recorded along with a daily ultrafiltration volume. Samples of serum and peritoneal fluid effluent will be frozen -20C for any future studies. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04923295
Study type Interventional
Source An-Najah National University
Contact
Status Completed
Phase N/A
Start date June 2, 2021
Completion date July 28, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04034628 - Improving the Outcomes of Peritoneal Dialysis (PD) Catheter Insertion
Completed NCT03569410 - The Effect of Natural Protein vs. Protein Supplements on Peritoneal Dialysis Patients N/A
Completed NCT04302649 - Dialysate Temperature in Peritoneal Dialysis Phase 4
Enrolling by invitation NCT05250752 - Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment Phase 2
Recruiting NCT03563898 - Feasibility and Safety in the Management of Fluid Overload in Peritoneal Dialysis Patients Through Sweat Stimulation With the Use of Portable Sauna Bath, Pilot Study N/A
Recruiting NCT03046511 - Peritonitis Prevention After Insertion of Peritoneal Dialysis Catheter. Phase 3
Not yet recruiting NCT05224466 - Characteristics and Clinical Outcomes of Peritoneal Dialysis Patients
Completed NCT03458819 - EMT in Peritoneal Dialysis Patients
Recruiting NCT06398977 - Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients N/A
Not yet recruiting NCT06045858 - SAFETY AND EFFICACY OF APIXABAN VERSUS WARFARIN IN PERITONEAL DIALYSIS PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION: A PROSPECTIVE, RANDOMISED, OPEN-LABEL, BLINDED END-POINT TRIAL (APIDP2) Phase 3
Active, not recruiting NCT04034966 - Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis N/A
Not yet recruiting NCT05715814 - meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis Phase 3
Recruiting NCT03148002 - Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation Phase 4
Recruiting NCT04572724 - The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value Phase 4
Completed NCT05797181 - The Effect Of Medical Nutritional Therapy On Patients With Sarcopenic Obesity Receiving Peritoneal Dialysis Treatment N/A
Recruiting NCT01893710 - International (Pediatric) Peritoneal Biobank
Completed NCT03382444 - The Kidney and The Brain Study - Assessment of Cognitive Impairment in Advanced CKD
Completed NCT04046263 - Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients Phase 4
Completed NCT03759002 - Association of Mean Platelet Volume and Cardiovascular Disease in Children With End Stage Renal Disease.
Completed NCT04176627 - Assessing Fluid Status of Peritoneal Dialysis Patients With Assistance of Lung Ultrasound